Zepbound®

Zepbound® (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It helps regulate how the body processes sugar, enhances insulin release after meals, and reduces appetite, supporting gradual and sustainable weight loss.

Eligibility:
Patients with a BMI of 30 or higher, or 27+ with a weight-related condition (such as type 2 diabetes, high blood pressure, or high cholesterol), may qualify. In some cases, patients with a BMI above 25 may also be eligible depending on their medical history.

Provider Review:
Licensed providers review each intake asynchronously — no live visit required. If additional information is needed, they will follow up through a secure patient portal. Your provider will personalize your plan and adjust the dosage over time to optimize results and minimize side effects.

Process:

1. Complete your secure online intake form.
2. A licensed provider reviews your medical history (typically within 24 hours).
3. If approved, your prescription is prepared and shipped directly to you.

Expectations:

• Weeks 1–4: Many patients notice reduced appetite and fewer cravings.
• Weeks 8–12: Clinical studies show measurable weight loss and improved metabolic markers.
• 6 months and beyond: Most patients experience steady progress with continued provider support and dose adjustments.

Pricing details are provided after eligibility confirmation. Costs vary depending on factors such as prescription dosage, pharmacy rates, and plan duration.